March 25, 2014

PaxVax to Present at the 21st Annual BioCentury Future Leaders in the Biotech Industry Conference

Presentation and Webcast Held Friday, March 28 at 9:30 a.m. Eastern Time

MENLO PARK and SAN DIEGO – MARCH 25, 2014 – PaxVax Inc., a specialty vaccine company focused on travelers and biodefense markets with a social mission to ensure global access to its vaccines, today announced that Kenneth Kelley, Chief Executive Officer of PaxVax, will present at the BioCentury Future Leaders in the Biotech Industry Conference in New York. Mr. Kelley’s presentation is scheduled for 9:30 a.m. EDT on Friday, March 28th in Presentation Room 402/403 at the Millennium Broadway Hotel & Conference Center. A Breakout Session will follow from 10:00 – 10:30 a.m. EDT in Breakout Room 401.

About PaxVax

PaxVax is a privately held specialty vaccine company founded in 2007. PaxVax is focused on traveler vaccines with an emerging pipeline in biodefense coupled with a social mission to ensure global access to its vaccines. PaxVax’s clinical-stage product portfolio includes an oral, single-dose cholera vaccine in Phase 3 clinical trials, a pandemic H5N1 influenza vaccine that recently concluded a successful Phase 1 clinical trial, and two anthrax vaccines. The company’s proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target any viral or bacterial protein antigen. PaxVax’s vaccine candidates are designed to enhance the desired immune response as well as offer an easier way to manufacture, store, distribute, administer, and deliver across the globe than conventional injectable vaccines. PaxVax is headquartered in Menlo Park, California with research and development laboratories and a state-licensed Good Manufacturing Practice (GMP) production facility in San Diego, California.

More information about PaxVax is available at www.PaxVax.com.

Download Press Release
PaxVax to Present at the 21st Annual BioCentury Future Leaders in the Biotech Industry Conference